• Cédric Jacqueline, Gilles Amador, Jocelyne Caillon, Virginie Le Mabecque, Eric Batard, Anne-Françoise Miègeville, Donald Biek, Yigong Ge, Gilles Potel, and Antoine Hamel.
• Université de Nantes, Faculté de Médecine, Thérapeutiques Cliniques et Expérimentales des Infections, EA3826, F-44000 Nantes, France. cedric.jacqueline@univ-nantes.fr
• J. Antimicrob. Chemother. 2010 Aug 1; 65 (8): 1749-52.

ObjectivesTo evaluate the activity of a new cephalosporin, ceftaroline, in comparison with other antistaphylococcal drugs (linezolid and vancomycin) at projected human therapeutic doses against methicillin-resistant Staphylococcus aureus (MRSA) and glycopeptide-intermediate S. aureus (GISA) strains.MethodsUsing a rabbit experimental model of acute osteomyelitis, efficacy was assessed following 4 days of treatment by colony counts of infected bone tissues (joint fluid, femoral bone marrow and bone).ResultsAlthough vancomycin remains the standard treatment for MRSA osteomyelitis, it was ineffective against the MRSA strain and poorly active against GISA infections in this model. Ceftaroline and linezolid demonstrated significant activity in bone marrow and bone, and were significantly better than vancomycin treatment. However, ceftaroline was the only drug to exhibit significant activity against MRSA in infected joint fluid.ConclusionsThe present study supports ceftaroline as a promising therapeutic option for the treatment of severe MRSA infections, including osteomyelitis.

28 keywords...

hide…